MZB1

Across TCGA pan-cancer cohorts, MZB1 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated MZB1 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MZB1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MZB1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

PDAC, GBM, and CCRCC are the cancer types where MZB1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	II,III,IV	0.515	0.260	.002	52	view →
GBM	OS	Tertile	All	0.795	0.264	<.001	20	view →
CCRCC	OS	Tertile	II,III,IV	0.813	0.474	.012	13	view →
LUAD	DFS	Quartile	II,III,IV	0.701	0.233	.002	13	view →
COAD	DFS	Median	IV	1.000	0.605	.043	6	view →
UCEC	DFS	Quartile	All	0.693	0.910	.036	4	view →
LSCC	DFS	Quartile	II,III,IV	0.515	0.881	.018	4	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

MZB1–PDAC (OS)

Open the PDAC breakdown →